申请人:——
公开号:US20040077031A1
公开(公告)日:2004-04-22
The present invention uses the manganese-dependent physiological form of the enzyme methionine aminopeptidase type 2 to assess inhibition by agents that might be used in the treatment of angiogenesis, cancer, malaria and leishmaniasis. This method has the advantage of using the manganese form of the enzyme and therefore, the advantage of identifying potent inhibitors that might not show activity in cellular systems because the wrong metal cofactor is used. Therefore it is a new tool for the development of agents useful in the therapy of cancer and other angiogenesis-related diseases and, several infectious diseases including malaria, leishmaniais and microsporidiosis.
本发明利用蛋氨酸氨肽酶 2 型的锰依赖生理形式来评估可能用于治疗血管生成、癌症、疟疾和利什曼病的药物的抑制作用。这种方法的优点是使用了锰形式的酶,因此可以鉴定出有效的抑制剂,而这些抑制剂可能因为使用了错误的金属辅助因子而无法在细胞系统中显示出活性。因此,这是一种新的工具,可用于开发治疗癌症、其他血管生成相关疾病以及包括疟疾、利什曼病和微孢子虫病在内的多种传染病的药物。